Improving the value and interpretation of observational studies comparing treatment effects of osteoporosis medications depends on standardized reporting of methods

J Bone Miner Res. 2024 Aug 5;39(7):807-809. doi: 10.1093/jbmr/zjae099.

Kaleen N Hayes^{1

2}, Arman Oganisian³, Douglas P Kiel^{4

5

6}

¹ Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI 02903, United States.
² Center of Innovation in Long-Term Services and Supports, Providence Veterans Affairs Medical Center, Providence, RI 02908, United States.
³ Department of Biostatistics, Brown University School of Public Health, Providence, RI 02903, United States.
⁴ Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA 02131, United States.
⁵ Department of Medicine, Harvard Medical School, Boston, MA 02115, United States.
⁶ Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, United States.

No abstract available

Keywords: bisphosphonates; denosumab; osteoporosis; pharmacoepidemiology; research methodology.

Publication types